Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$13.85 USD

13.85
2,085,853

+0.35 (2.59%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $13.84 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Biohaven (BHVN) Might Surprise This Earnings Season

by Zacks Equity Research

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

by Zacks Equity Research

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

Zacks Equity Research

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

by Zacks Equity Research

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Zacks Equity Research

Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

Zacks Equity Research

Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

by Zacks Equity Research

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

Zacks Equity Research

Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate

by Zacks Equity Research

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Zacks Equity Research

Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising

by Zacks Equity Research

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Zacks Equity Research

Why Earnings Season Could Be Great for Biohaven (BHVN)

by Zacks Equity Research

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.